Position paper on tuberculosis screening in patients with immune mediated inflammatory diseases candidates for biological therapy

Duarte R1,5,6, Campainha S1,5,6, Cotter J2,8, Varela P5,9, Correia A1,10, Canhão H3,9, Fonseca JE4,11,12, on behalf of Portuguese Society of Pulmonology, Portuguese Society of Gastroenterology, Portuguese Society of Dermatology and Venereology and Portuguese Society of Rheumatology.

ABSTRACT

Chronic immunosuppression is a known risk factor for tuberculosis. Our aim was to reach a consensus on screening and prevention of tuberculosis in patients with immune mediated inflammatory diseases candidates to biologic therapy.

Methods: Critical appraisal of the literature and expert opinion on immunosuppressive therapies and risk of tuberculosis.

Results and Conclusion: The currently recommended method for screening is the tuberculin skin test and the interferon gamma assay, after exclusion of active tuberculosis. Positively screened patients should be treated for latent tuberculosis infection. Patients may start biological therapy after 1 to 2 months, as long as they are strictly adhering to and tolerating their preventive regimen.

Keywords: Tuberculosis screening; Latent tuberculosis; Biological therapies; Anti-TNF drugs; Immune mediated inflammatory diseases.

INTRODUCTION

In populations with high incidence of tuberculosis (TB), there have been an increased number of TB cases reported in patients treated with tumor necrosis factor antagonists (anti-TNF)1. In fact, the relative risk (RR) of developing TB is 1.6-25.2 times higher in Rheumatoid Arthritis (RA) patients under anti-TNF therapy than in RA patients treated with conventional immunosuppressive therapy, depending on the clinical setting and the anti-TNF used1-7.

Active TB in the context of anti-TNF therapy usually results from the reactivation of a latent infection, shortly after the beginning of the treatment5,8. TB often presents an atypical behaviour, which may pose difficulties to the diagnosis9. In countries with high incidence of TB, cases caused by new infection are also particularly frequent. TNF is fundamental for the immunological defence against Mycobacterium tuberculosis, especially in the formation and maintenance of granulomas. Animal models confirmed that it is possible to reactivate TB after administering anti-TNF antibodies10.

Besides anti-TNFs, other biological agents were approved for immune mediated inflammatory diseases treatment. Data about the risk of developing TB infection in patients treated with these other agents are scarce. Even though this risk might be lower for some of the biological agents that do not interfere with TNF until more data is available this group assumed that this position paper should be applied to all biological treatments.

Preventive chemotherapy can significantly reduce the incidence of active TB in individuals with latent infection, identified by positive tuberculin skin test (TST) or interferon-γ release assay (IGRA)11.

The currently available evidence about the best management to prevent TB in patients receiving biological therapy is limited. In this position paper on the
screening and prevention of TB in patients treated with biological therapy, delegates from the Tuberculosis Committee (TC) of the Portuguese Pulmonology Society (SPP), the Rheumatoid Arthritis Study Group (GEAR) of the Portuguese Society of Rheumatology (SPR), the Portuguese Society of Dermatology and Venereology (SPDV) and the Portuguese Society of Gastroenterology (SPG), have revised and updated recommendations that had been previously developed by the GEAR - SPR and by the TC – SPP, first published in 2006 and latter updated in 2008.

The main objective of this position paper is to contribute for the reduction of the number of cases of reactivated TB and new TB infections in patients with immune mediated inflammatory diseases who are candidates for treatment with biological therapy in Portugal. An additional objective is to standardize the procedures used to screen and prevent TB in the initial assessment of these patients, preferably at disease onset, before the beginning of any immunosuppressant therapy.

RECOMMENDATIONS

WHO SHOULD BE SCREENED?

All patients with immune mediated inflammatory diseases candidates for the use of biological therapy should be screened for latent TB infection (LTBI) prior to starting therapy (Evidence level C)

Patients eligible for anti-TNF therapy have an increased risk of developing TB upon starting this treatment. TB in this setting can present with severe, atypical and life-threatening manifestations. This risk exists not only due to the biological importance of TNF in the initiation and maintenance of the response against Mycobacterium tuberculosis, but also because the underlying diseases (eg. RA) and concomitant treatments (eg. steroid therapy) increase the risk of TB per se. Most of the active TB cases in patients treated with anti-TNF are due to reactivation of LTBI. It is well known that screening for LTBI before starting anti-TNF therapy is effective in preventing reactivation of TB. Therefore, all national guidelines recommend the exclusion of active TB disease and LTBI in patients in whom biological therapy is considered.

WHEN TO SCREEN?

Patients with immune mediated inflammatory diseases should be screened for TB before

STARTING BIOLOGIC TREATMENT AND IDEALLY WHEN THE DISEASE IS DIAGNOSED (Evidence level C)

Any candidate to biological therapy should be screened for the presence of specific immune response to M. tuberculosis (including TST and IGRA) before starting these drugs and ideally when the immune mediated inflammatory disease is diagnosed, except in patients with mild forms of psoriasis, treated with topical drugs.

It has been shown that certain diseases, such as RA, as well as chronic immunosuppressive therapy, such as corticosteroids (> 15mg/day for more than 2 weeks) increase the risk of TB. In addition, it is also well known that immunosuppressive therapy compromises the sensitivity of the TST and IGRA, being this especially true for TST. Therefore, it is highly desirable that the first screen for TB should be done at the moment of diagnosis, before any kind of immunosuppressive treatment or phototherapy is started.

WHICH TESTS SHOULD WE USE?

After exclusion of active TB, LTBI should be screened with TST and IGRA (Evidence level C and D)

In the light of current knowledge, and in the absence of a gold standard test for LTBI diagnosis, the screening process for LTBI requires a combination of a detailed medical history (which should include ethnicity, country of birth, history of or recent exposure to TB, previous TB and respective treatment, co-morbidities associated with increased risk of TB, professional activities with increased risk of exposure to TB), travel to endemic areas, chest radiograph (searching for changes indicative of active or residual previous TB) and tests for immunological memory against M. tuberculosis (TST and IGRA). In erythodermic psoriasis TST may be impossible to perform, reinforcing the need of IGRA in these cases.

The sensitivity of both tests may be compromised in patients receiving immunosuppressive therapy, although published evidence suggests that IGRA has a higher sensitivity than TST in patients with immune mediated inflammatory diseases, even after starting immunosuppressive therapy.

Currently, different guidelines are adopted regarding the use of TST and IGRA, reflecting the difficulty of choosing the best strategy. Overtreatment, implying the risk of drug toxicity due to a false-positive screening and undertreatment due to a false-negative screening are the main concerns.
Since the increase in sensitivity and specificity provided by IGRA in different studies is controversial and their positive and negative predictive values are yet to be defined, the role of IGRA is still under investigation. In this sense, IGRA cannot yet be used as a single test for immunological memory to *M. tuberculosis*. Thus, currently it is prudent to use both TST and IGRA in order to maximize sensitivity and specificity.

Since patients may have false negative TST due to immunosuppression, a two step approach is advised – repeat TST 1-3 weeks after the initial negative screening.

**HOW TO EXCLUDE ACTIVE TB IN PATIENTS WITH CROHN’S DISEASE?**

**ACID FAST BACILLI SM EAR AND CULTURE SHOULD BE PERFORMED IN ENDOSCOPIC BIOPSIES (EVIDENCE LEVEL C)**

The distinction between Crohn's disease and intestinal TB is a diagnostic challenge, as they present similar clinical, radiological, endoscopic and histological features.

Investigation of patients with suspected Crohn's disease should always include differential diagnosis with intestinal TB. Acid fast bacilli smear and culture are warranted in pathological examination of endoscopic biopsies. Other tests such as nucleic acid amplification, immunohistochemistry or in situ hybridization are promising techniques that have been evaluated in some studies, but they are not widely available and require further validation.

**HOW TO INTERPRET THE TST?**

**TST IS CONSIDERED POSITIVE IF INDURATION IS ≥5MM IN PREVIOUSLY IMMUNOSUPPRESSED PATIENTS AND IF ≥10MM IN PATIENTS NOT PREVIOUSLY EXPOSED TO IMMUNOSUPPRESSORS (EVIDENCE LEVEL D)**

In order to increase the sensitivity of TST (at the expense of lower specificity) different guidelines recommend, in the immunocompromised population, an induration of ≥5 mm to be the cut-off for a positive TST.

The Tuberculosis Network European Trials Group (TBNET) recommends a cut-off value of 10 mm, stating that the loss of sensitivity to detect infection by increasing the cut-off from 5 to 10 mm is marginal, while the gain in specificity is substantial. Taking this into consideration, TBNET suggests that a TST ≥10 mm should lead to LTBI treatment, without requiring IGRA confirmation. This evidence is based on results of non-controlled and non randomized trials and on observational studies.

According to the Portuguese clinical practice, patients with immune mediated inflammatory diseases, who are candidates for anti-TNF therapy, should undergo a TST: the test is considered positive in previously immunosuppressed patients if the induration is ≥5 mm and in patients not previously exposed to immunosuppressors if the induration is ≥10 mm.

**WHO SHOULD START LTBI TREATMENT?**

**PATIENTS WITH EPIDEMIOLOGICAL RISK FACTORS FOR TB (HISTORY OF EXPOSURE TO TB, PREVIOUS TB, EMIGRANTS FROM HIGH TB PREVALENCE AREAS, RESIDENTS IN HIGH INCIDENCE AREAS, COMORBIDITIES ASSOCIATED WITH INCREASED RISK OF TB, PROFESSIONAL ACTIVITIES WITH INCREASED RISK OF EXPOSURE TO TB, TRAVEL TO ENDEMIC AREAS), OR CHEST X-RAY SEQUELAE OF UNTREATED PREVIOUS TB, OR POSITIVE TST AND/OR IGRA, SHOULD START LTBI TREATMENT, AFTER EXCLUSION OF ACTIVE TB. (EVIDENCE LEVEL C AND D):**

Whenever there is evidence of exposure to TB (regardless the results of the screening and after exclusion of active TB) or LTBI (positive TST and/or IGRA or changes in chest radiograph suggestive of previous untreated TB), after exclusion of active TB, preventive treatment should be offered before initiating biological therapy, as these patients have a high risk of progression to disease.

Due to the risk of serious forms of disease, treatment must be offered to candidates for biological therapy regardless of age and presumed date of infection.

**WHICH LTBI TREATMENT REGIMEN SHOULD BE USED?**

**ISONIAZID FOR 9 MONTHS (EVIDENCE LEVEL C AND D):**

Several therapeutic strategies have been proposed. Isoniazid is classically recommended as this drug in immunocompromised patients has proven to be effective (data derived from multiple studies in HIV patients). Isoniazid for a period of 9 months is the most commonly used regimen and has an estimated efficacy of around 90%. This regimen is recommended by the American Thoracic Society (ATS) and Canadian Tuberculosis Standards, while the 6 months regimen, in which effectiveness varies be-
between 65-69\%, is proposed by the National Institute for Health and Clinical Excellence (NICE)\(^6\).

TBNET recommends treatment with isoniazid for 9 to 12 months or isoniazid and rifampicin for 3 months (3HR)\(^9\). However, the later is associated with a lower efficacy (around 60\%). Some studies indicate that 4 months of rifampicin (4R) are at least as effective as 3HR and this regime has the advantage of being better accepted by patients, having fewer adverse effects when compared with regimens based on isoniazid and is associated with a lower cost to the health system\(^65-69\). These are very relevant advantages but effectiveness remains uncertain, as this regimen has not yet been tested extensively in randomized trials.

In light of current knowledge, treatment with isoniazid for 9 months is the most consensual option\(^19,60,61\). One month is defined as the minimum LTBI treatment duration before starting biological drugs\(^19\). This recommendation is based on expert opinion.

**EVALUATION OF THE RISK FOR TOXICITY DUE TO LTBI TREATMENT**

**PATIENT EDUCATION, CLINICAL MONITORING, BASELINE AND MONTHLY LABORATORY TESTING OF LIVER ENZYMES (EVIDENCE LEVEL C AND D):**

Given the high risk of TB in patients starting anti-TNF, the risk of age-related hepatotoxicity\(^7\) should not prevent patients from receiving treatment for LTBI. In addition to liver toxicity, isoniazid is associated with toxicity to the nervous system\(^7\). Vitamin B6 reduces central and peripheral effects of isoniazid and should be given to individuals with a history of alcoholism, diabetes, pregnant, postpartum, infants, malnourished, HIV-positive, people with active liver disease, cancer or history of pre-existing peripheral neuropathy\(^7\).

In case of choosing rifampicin-based regimens, interactions with other drugs should be considered, since this drug is a potent inducer of CYP450\(^7\). Besides patient education and clinical monitoring, baseline and monthly (or biweekly) laboratory testing of liver enzymes is recommended for people older than 35 years, chronic alcohol abusers, HIV-infected persons, females during pregnancy and within 3 months after delivery and for those with chronic liver disease or taking potentially hepatotoxic concomitant medications. Transient transaminase elevations are common and may reflect the process of hepatic adaptation. However, isoniazid and/or rifampicin should be withheld as recommended if the serum transaminase level is higher than three times the upper limit of normal in a symptomatic patient or five times the upper limit of normal in the absence of symptoms\(^61,62\).

A change of the therapeutic regimen for a less hepatotoxic one (as 4R, at the expense of effectiveness) should be considered when serious hepatotoxicity is limiting LTBI treatment with isoniazid.

**HOW SHOULD FOLLOW UP BE PERFORMED?**

Patients should be re-screened for LTBI if the previous screen had been negative and the patient had not started biologicals, to exclude possible infection in the meantime (in the absence of a known contact with a TB patient, the screen would be valuable for 6 months). In the event of contact with active TB, TB screening should be promptly performed and in the absence of disease and LTBI, chemoprophylaxis should be guaranteed\(^19\).

Annual testing is recommended for patients, who live, travel or work in environments where TB exposure is likely, while they continue treatment with biologic agents. Patients who tested positive for TST and IGRA should only be monitored for clinical signs of TB.

**SUMMARY**

1. All candidates for biologic therapy should be screened for TB.
2. TB screening procedures should include risk assessment, evaluation of TB signs and symptoms, chest radiography, TST and IGRA.
3. After exclusion of active TB, the presence of a positive TST (≥ 10 mm in immunocompetent or ≥ 5 mm in immunocompromised conditions) or positive IGRA indicates the possibility of LTBI and LTBI therapy should be offered.
4. The existence of an untreated or inadequately treated previous TB (determined by chest X-ray sequelae and/or clinical history) should be evaluated for active TB and, if that is excluded, LTBI treatment should be given.
5. In the event of a recent exposure to a TB patient, LTBI therapy should be offered, even in the presence of negative screening tests.
6. The recommended regimen for LTBI treatment is 9 months of isoniazid.
7. Annual testing is recommended while on biological treatment.

---

\(^{6}\) National Institute for Health and Clinical Excellence (NICE)

\(^{9}\) Treatment with isoniazid and rifampicin for 3 months (3HR)

\(^{19}\) Treatment with isoniazid for 9 months

\(^{60,61}\) Minimum LTBI treatment duration before starting biological drugs

\(^{7}\) Age-related hepatotoxicity

\(^{65-69}\) Isoniazid and rifampicin regimens

\(^{76,77}\) Isoniazid and rifampicin

\(^{61,62}\) Serum transaminase levels

\(^{7}\) Hepatic adaptation

\(^{61,62}\) LTBI treatment with isoniazid

\(^{61,62}\) Hepatotoxicity

\(^{61,62}\) LTBI therapy

\(^{61,62}\) Immunocompetent

\(^{61,62}\) Immunocompromised conditions

\(^{61,62}\) LTBI screening

\(^{61,62}\) LTBI therapy

\(^{61,62}\) Annual testing

---
Este artigo terá publicação simultânea na Revista Portuguesa de Pneumologia, no Jornal Português de Gastroenterologia (GE) e na Revista da Sociedade Portuguesa de Dermatologia e Venereologia.

CORRESPONDENCE TO
Raquel Duarte
Departamento de Epidemiologia Clínica,
Medicina Preventiva e Saúde Pública
Faculdade de Medicina da Universidade do Porto
Alameda Prof Hernani Monteiro
4200-319 Porto
E-mail: rdmelo@med.up.pt

REFERENCES
22. Lalvani A, Millington K. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmune Reviews 2008; 8: 147-152.


45. Amarapurkar D, Patel N, Rane P. Diagnosis of Crohn’s disease in India where tuberculosis is widely prevalent. World J Gastroenterol 2008; 14:741-746.


34TH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR BONE AND MINERAL RESEARCH

Minneapolis, Minnesota
EUA, 12 a 16 Outubro 2012

SPARKLE – SPONDYLOARTHRITIS KNOWLEDGE AND LEARNING

Óbidos, Portugal
19 a 10 Outubro 2012
ANEXOS
CARTA TIPO DE ENVIO A CONSULTA DE TUBERCULOSE

Caro Colega,

Envio-lhe o doente __________________________ seguido por mim com o diagnóstico de______________, estabelecido em (data) ____________ (se se tratar de doença de Chron especificar se foi feito estudo micobacteriológico e resultado).

Está atualmente medicado com ___________________________________________ e o meu objetivo é iniciar terapêutica com ____________ dentro de _____ meses..

(Se tiver estudo analítico recente com transaminases, enviar)

O colega ao dispor,

XXXXXX

O contacto para qualquer esclarecimento adicional: __________________________

CARTA TIPO DE RESPOSTA DA CONSULTA DE TUBERCULOSE

Caro Colega,

Enviou-nos o/a Sr/a _____________________________________ seguido/a por si por ____________ , medicado com ___________________ e candidato a iniciar ____________________.

Da avaliação de fatores de risco para infeção por Mycobacterium tuberculosis
• Com/Sem história de exposição a doentes com tuberculose no passado
• Com/Sem história pessoal de tuberculose

Se houver história de exposição a tuberculose no passado:
A exposição a doente com tuberculose decorreu há ______ meses/anos. Foi efetuado/Não foi efetuado rastreio, tendo/Não tendo feito medicação preventiva com ____________ durante ________ meses.

Se houver história de tuberculose no passado:
O diagnóstico de TB no passado foi baseado em _______________ (confirmação cultural/histologia/clinica e radiologia sugestiva). Teve/Não teve resultado do teste de suscetibilidade aos fármacos. Fez/Não fez tratamento.

Se fez tratamento
Fez tratamento com ___________________ durante ________ meses em regime de ___________________
(toma observada diretamente ou livre).

ÓRGÃO OFICIAL DA SOCIEDADE PORTUGUESA DE REUMATOLOGIA
Se foram efectuados rastreios anteriores:

<table>
<thead>
<tr>
<th>Data</th>
<th>Com medicação imunossupressora? (sim/não)</th>
<th>Exposição conhecida? (sim/não)</th>
<th>Radiografia</th>
<th>TST (mm)</th>
<th>IGRA</th>
<th>Fez medicação preventiva? Se sim, que esquema?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Do rastreio actual**

Com/sem sintomas sugestivos de doença
Radiografia pulmonar_____________________________(Normal/alterada. Se alterada descrever as alterações).
Teste tuberculinico (two steps): _________________ mm
IGRA: _______________________(positivo/negativo/indeterminado)
Se IGRA indeterminado: mitogéniadc________________controlo_____________

**Da avaliação de fatores de risco para toxicidade com antibacilares**

Efectuado estudo analítico com transaminases que foram____________(normais/alteradas). Não há/ há outros fatores de risco para toxicidade para antibacilares (se sim, quais)__________________________.

Assim, o doente tem indicação/não tem indicação para iniciar tratamento preventivo com isonaizida/rifampicina/isoniazida+rifampicina durante um período de ________meses. Poderá iniciar medicação biológica dentro de 4 semanas se não ocorrerem intercorrências.

____________. ___/___/

O colega ao dispor,
XXXXXXX

O contacto para qualquer esclarecimento adicional:__________________________
### PROTOCOLO DE ACTUAÇÃO PARA RASTREIO DE DOENTES CANDIDATOS A TRATAMENTO IMUNOSUPRESSOR

| Data: _____/____/_______ | N.º Processo: ____________ | Médico: ________________ |

#### 1. Identificação do doente

| Nome: ________________________________________________ |
| Sexo: M □ F □ | Data nascimento: ____/____/_______ | Profissão: _________________________ |
| Hábitos tabágicos: Não □ Sim □ (_____ UMA) |
| Consumo álcool: Não □ Sim □ (_____ g/dia) | Observações: ________________________________ |

#### 2. Informação sobre a doença

| Diagnóstico: ___________________________________________ | Data do diagnóstico: ____/____/_______ |
| Tem indicação actual para iniciar tratamento imunosupressor? Sim □ Não □ |
| Se medicação biológica, qual? ____________________________ |
| Se outros imunosupressores, quais? _________________________ |
| VIH positivo ou outro estado de imunosupressão? ________________ |

<table>
<thead>
<tr>
<th>Medicamento</th>
<th>Sim</th>
<th>Não</th>
<th>Dose</th>
<th>Data início/Data fim</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corticóides</td>
<td></td>
<td></td>
<td></td>
<td><strong><strong>/</strong></strong>/<em><strong><strong><strong>; <strong><strong>/</strong></strong>/</strong></strong></strong></em></td>
</tr>
<tr>
<td>Metotrexato</td>
<td></td>
<td></td>
<td></td>
<td><strong><strong>/</strong></strong>/<em><strong><strong><strong>; <strong><strong>/</strong></strong>/</strong></strong></strong></em></td>
</tr>
<tr>
<td>Ciclosporina</td>
<td></td>
<td></td>
<td></td>
<td><strong><strong>/</strong></strong>/<em><strong><strong><strong>; <strong><strong>/</strong></strong>/</strong></strong></strong></em></td>
</tr>
<tr>
<td>Azatioprina</td>
<td></td>
<td></td>
<td></td>
<td><strong><strong>/</strong></strong>/<em><strong><strong><strong>; <strong><strong>/</strong></strong>/</strong></strong></strong></em></td>
</tr>
<tr>
<td>Ciclofosfamida</td>
<td></td>
<td></td>
<td></td>
<td><strong><strong>/</strong></strong>/<em><strong><strong><strong>; <strong><strong>/</strong></strong>/</strong></strong></strong></em></td>
</tr>
<tr>
<td>Outros</td>
<td></td>
<td></td>
<td></td>
<td><strong><strong>/</strong></strong>/<em><strong><strong><strong>; <strong><strong>/</strong></strong>/</strong></strong></strong></em></td>
</tr>
</tbody>
</table>

#### 3. Informação sobre antecedentes

| Exposição anterior a caso de TB? Sim □ Não □ |
| Se sim, em que ano? ________________ | Tipo de exposição: ________________________________ |
| Rastreio TB anterior? Sim □ Não □ | Se sim, resultados: ________________ |

*continua na página seguinte*
### 4. Rastreio actual

<table>
<thead>
<tr>
<th>Questão</th>
<th>Sim</th>
<th>Não</th>
<th>Observações</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fez tratamento de infecção latente por Mt?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Se sim, durante quanto tempo (meses)?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antecedentes de TB activa?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Se sim, em que ano?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fez tratamento de TB activa?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Se sim, qual o tratamento e durante quanto tempo (meses)?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sintomas?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Observações:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quais?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rx tórax?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resultado:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Se sintomas sugestivos e/ou alterações compatíveis com TB no Rx:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baciloscopia?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data: <strong>/</strong>/________</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resultados/Observações:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TC tórax?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data: <strong>/</strong>/________</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resultados/Observações:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Se diagnóstico de Doença de Crohn, fez:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Exame directo da biopsia intestinal?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resultado/Observações:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Cultura da biopsia intestinal?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resultado/Observações:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• TAAN na biopsia intestinal?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resultado/Observações:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Se foi excluída TB doença:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TST (two steps):</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sim</td>
<td>Não</td>
<td>Resultado: _____ (mm)/ _____ (mm)</td>
<td></td>
</tr>
<tr>
<td>IGRA:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sim</td>
<td>Não</td>
<td>Resultado:</td>
<td></td>
</tr>
</tbody>
</table>

*continua na página seguinte*
5. Algoritmo de decisão para elegibilidade para tratamento de infecção tuberculosa latente (Se sequelas de TB ou nódulos de Gohn em doente que nunca efectuou tratamento antibacilar ou se história de exposição a tuberculose ativa, passa a elegível para tratamento independentemente do resultado do TST ou do IGRA)

6. Risco de toxicidade

Consumo álcool: Sim ☐ Não ☐ (______ g/dia)

Patologia hepática: Sim ☐ Não ☐ Observações: ____________________________________________

Consumo habitual de medicamentos: Sim ☐ Não ☐ Quais? ____________________________________

Estudo analítico:

<table>
<thead>
<tr>
<th>Análise</th>
<th>Data</th>
<th>Resultado</th>
</tr>
</thead>
<tbody>
<tr>
<td>TGO</td>
<td><strong><strong>/</strong></strong>/_______</td>
<td></td>
</tr>
<tr>
<td>TGP</td>
<td><strong><strong>/</strong></strong>/_______</td>
<td></td>
</tr>
<tr>
<td>Outra</td>
<td><strong><strong>/</strong></strong>/_______</td>
<td></td>
</tr>
</tbody>
</table>

7. Proposta terapêutica (após avaliação do risco de toxicidade)

Tratamento de infecção tuberculosa latente: Sim ☐ Não ☐ Esquema: __________ Duração prevista: ____ (meses)

Tratamento de tuberculose activa: Sim ☐ Não ☐ Esquema: __________ Duração prevista: ____ (meses)

continua na página seguinte
8. Vigilância do tratamento

<table>
<thead>
<tr>
<th>Vigilância</th>
<th>Deve incluir</th>
<th>Em relação ao início do tratamento</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clínica</td>
<td>• Sinais ou sintomas de efeitos adversos</td>
<td>• 15 dias, 1 mês, 2 meses e depois de 2/2 meses</td>
</tr>
<tr>
<td>Laboratorial</td>
<td>• TGP/TGO</td>
<td>• 15 dias, 1 mês, 2 meses e depois de 2/2 meses</td>
</tr>
<tr>
<td></td>
<td>• Hemograma e bilirrubina (se tratamento com R)</td>
<td>• Mensal se VIH, álcool, doença hepática prévia, fármacos hepatotóxicos, gravidez ou pós-parto, utilizador de drogas, idade&gt; 35 anos</td>
</tr>
</tbody>
</table>

Principais efeitos adversos

<table>
<thead>
<tr>
<th>Isoniazida</th>
<th>Rifampicina</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Hepatite</td>
<td>• Hepatite (colestática)</td>
</tr>
<tr>
<td>• Neuropatia periférica (parestesias, hipostesias, diminuição força muscular extremidades)</td>
<td>• Síndrome flu-like</td>
</tr>
<tr>
<td>• Sonolência, letargia</td>
<td>• Gastro-intestinais (dor abdominal, náuseas, vômitos)</td>
</tr>
<tr>
<td>• Rash cutâneo</td>
<td>• Reacção cutânea generalizada</td>
</tr>
<tr>
<td></td>
<td>• Púrpura trombocitopénica</td>
</tr>
</tbody>
</table>